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Interphase cytogenetics reveals a high incidence of aneuploidy and
intra-tumour heterogeneity in breast cancer
M Fiegll, C Tueni', T Schenk', R Jakesz2, M Gnant2, A Reiner3, M Rudas3,
H Pirc-Danoewinatal, C Marosil, H Huber' and J Drachl
'First Department ofInternal Medicine, Division ofClinical Oncology, 2Department ofSurgery and 3Department ofClinical
Pathology, University- of Vienna, Vienna, Austria.
Summary The occurrence of aberrations involving chromosomes 11 and 17 in malignant tissues of breast
cancer patients has not yet been studied systematically. Using fluorescence in situ hybridisation (FISH) with
centromere-specific probes, we determined chromosome 11 and 17 status in interphase nuclei from primary
and or metastatic breast cancer cells. In all cancerous specimens obtained from 30 patients, FISH identified
cells with clonal chromosomal abnormalities, with aneuploidy rates ranging from 6% to 92% (median 59%).
There was a gain of centromeric signals for chromosome 11, most likely corresponding to hyperploidy;
aberrations of chromosome 17 in specimens from 26 patients (87%) were hyperploid as well; however, four
cases (13%) showed loss of chromosome 17 centromeres. All specimens contained heterogeneous aneuploid
cell populations with excessive gain of signals in some cases. The pattern of aneuploidy did not appear to
correlate with tumour grade,stage and was comparable in primary tumours and corresponding metastatic
axillary lymph nodes, indicative of genetic instability early in tumour development. Screening with a panel of
FISH probes may lead to enhanced sensitivity and specificity in detecting malignant cells, as demonstrated in
this study with effusions which could not be conclusively interpreted as being malignant by cytological criteria.
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Metaphase karyotyping of solid tumours is of great value in
defining chromosomal features potentially responsible for
tumorigenesis, but classical cytogenetics is extremely lab-
orious and has been hampered by the usually low mitotic
index of tumour cells in vitro. Targeting of specific
chromosomal regions in interphase nuclei by fluorescence in
situ hybridisation (FISH) (Cremer et al., 1986; Pinkel et al.,
1986) offers the possibility of detecting chromosomal aberra-
tions in a large number of tumour cells independent of their
proliferative capacity. FISH has revealed new insights into
tumour biology (reviewed by Le Beau, 1993; Wolman, 1994)
and, as a rapid and inexpensive technique, might gain impor-
tance in clinical oncology.
Several reports describe aberrations of chromosomes 11
and 17 in breast carcinoma, which harbour genes of
causative importance for tumorigenesis and propagation
(reviewed in Devilee and Cornelisse, 1994). However, a
systematic FISH study of the rate of chromosomal changes
in these chromosomes in malignant tissues of breast cancer
patients has not yet been performed. In this project, we have
used chromosome-specific c-satellite DNA probes and FISH
to determine aneuploidy of chromosomes 11 and 17 in




A total of 42 human cancerous specimens derived from 30
breast cancer patients (aged between 34 and 85 years, mean
age 59 years) were examined by FISH, including 17 primary
breast tumours (15 ductal and two lobular carcinomas), nine
pleural and four ascites aspirates and 12 tumour infiltrated
axillary lymph nodes. The 12 positive nodes were derived
from five patients whose primary tumours were also
evaluated. The specimens were sent to the laboratory directly
from the department of pathology. Grading of primary
tumours and stage of disease are summarised in Table I.
Cells obtained from ten effusions were cytologically compat-
ible with mammary carcinoma. With effusion cells from three
patients, the differential diagnosis between reactive and
malignant cells was difficult by cytological criteria only.
FISH and metaphase preparation
Mechanically disaggregated tumour cells were suspended in
phosphate-buffered saline (PBS), pelleted at 1000g, fixed in
methanol-acetic acid (3:1, v/v), and stored at -200C.
Ascites and pleural effusion cells were washed twice in PBS
and fixed as described above. Biotin-labelled a-satellite pro-
bes specific for the centromeric regions of human chromo-
somes 11 (probe DIIZI) and 17 (probe D17Z1) were
obtained from Oncor (Gaithersburg, MD, USA). The in situ
hybridisation procedure followed the protocol described
previously (Escudier et al., 1993). Metaphase preparation was
performed by standard techniques as detailed elsewhere (Pirc-
Danoewinata et al., 1994). Slides were R-banded and
chromosomes were classified according to the ISCN (Mitel-
man, 1991).
Analysis byfluorescence microscopy
Fluorescence signals in 200-600 non-overlapping interphase
nuclei with intact morphology were scored by two inves-
tigators using an Olympus AH-3 microscope with a 100 x
planar objective. Data are presented as the mean of these
counting results. We applied the criteria of FISH signal
analysis proposed in a previous report (Hopman et al., 1988).
All cells in a field except those with the typical morphology
of granulocytes were evaluated.
As controls, FISH of chromosomes 11 and 17 was con-
comitantly performed with peripheral blood mononuclear
cells from two healthy donors, with bone marrow cells from
a patient with melanoma (without marrow involvement by
histology) and with pleural effusion cells from a patient witih
reactive pleuritis. No significant differences in FISH results
between these tissues were noted in two separate experiments.
The portion of zero-spot cells (inversely corresponding to
the hybridisation efficiency) was below 1% both in all control
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Table I Anatomical site. pathology and distribution ofsignal numbers for chromosomes 11I and 17 in breast cancer cell specmens from 30 patients
evaluated by FISH'
Centromere copy- number (percentage")
Patient Chromosome 11 Chromosome 17
no. M4aterial Grade Stage'] I 3 4 S 6 7 8 1 2 3 4 .5 6 7 8
1 PT GI I 1.5 13.0 15.0 20.5 26.0 23.0 0.5 0.5 2.5 25.0 30.5 40.0 1.5 0.5 - -
2 PT GI I 0.5 19.0 76.5 4.0 - - - - 1.0 22.5 75.5 1.0 - - - -
3 PT GI II 60 88.0 2.5 3.5 - - - - 93.0 6.5 0.5 - - - - -
4 PT G2 I 5.5 62.5 30.0 1.5 0.5 - - - 8.0 36.0 8.0 12.5 20.0 13.0 1.5 1.0
5 PT G2 II 0.5 15.0 17.0 60.5 2.0 2.0 1.0 2.0 6.0 33.5 54.5 3.5 1.0 1.0 0.5 -
6 PT G2 II 4.5 91.0 1.5 2.5 0.5 - - - 4.0 32.5 60.0 1.5 1.0 1.0 - -
7 PT G2 II 9.0 68.5 21.5 1.0 - - - - 16.5 66.0 6.0 6.5 4.0 1.0 - -
8 PT G2 II 9.5 83.0 5.0 1.5 0.5 - - 0.5 48.5 47.5 2.5 0.5 0.5 0.5 - -
9 PT G2 II 5.589.0 2.0 3.5 - - - - 9.5 83.0 3.5 3.5 0.5 - - -
10 PIT G2 II 3.0 24.5 18.0 41.0 10.5 1.5 1.0 0.5 8.0 89.0 1.5 1.5 - - - -
11I PIT G3 II 1.0 15.5 77.0 3.0 1.5 2.0 - - 1.0 21.0 71.5 2.5 2.0 1.5 0.5 -
12 PT G3 II 2.5 24.0 70.0 2.0 1.0 0.5 - - 1.5 8.5 0.5 1.5 8.5 33.0 30.0 16.5
13 PT G3 II 2.5 20.0 6.0 68.0 1.0 1.0 0.5 1.0 2.5 14.5 3.0 8.5 32.5 36.5 1.5 1.0
14 PT G3 II 3.5 73.0 19.5 4.0 - - - - 4.5 71.5 5.0 17.0 1.5 0.5 - -
15 PT G3 III 4.0 25.0 70.5 0.5 - - - - 2.5 9.0 37.0 49.0 2.5 - - -
16 PT G3 IV 5.5 91.5 2.5 0.5 - - - - 6.0 37.0 54.5 1.0 0.5 1.0 - -
17 PIT G3 IV 4.0 61.0 32.0 2.0 0.5 0.5 - - 14.0 71.0 11.0 4.0 - - - -
18 P IV 2.0 84.0 2.5 10.0 - - 0.5 1.0 12.5 76.0 7.0 4.0 0.5 - - -
19 P IV 9.0 64.0 23.0 3.0 0.5 0.5 - - 8.0 82.0 7.0 2.5 0.5 - - -
20 P IV 14.0 32.0 21.5 20.0 3.5 4.0 1.5 3.5 9.0 44.0 33.5 1.0 3.5 8.0 0.5 0.5
21 P IV 35 88.0 4.5 4.0 - - - - 3.0 93.5 3.0 0.5 - - - -
22 P IV 1.0 45.0 46.0 4.5 1.0 2.5 - - 0.5 6.0 26.0 63.0 2.0 0.5 2.0 -
23 P IV 2.0 66.5 19.0 10.0 1.0 1.0 0.5 - 2.0 83.0 4.5 9.0 1.0 0.5 - -
24 P IV 2.0 78.0 10.0 9.5 0.5 - - - 8.0 86.0 4.0 2.0 - - - -
25 P IV 10 85.0 6.0 8.0 - - - - 2.0 84.5 10.0 3.5 - - - -
26 P IV 2.0 15.0 56.0 26.5 0.5 - - - 1.5 9.0 38.5 43.5 6.0 1.5 - -
27 A IV 7.5 76.0 3.5 9.5 1.0 1.0 1.0 0.5 15.5 79.0 3.0 1.0 0.5 0.5 0.5 -
2)8 A IV 0.5 24.0 65.0 7.5 - 1.5 0.5 1.0 1.5 89.5 7.0 2.0 - - - -
29 A IV 40 92.5 3.0 0.5 - - - - 93.5 6.0 0.5 - - - - -
30 A IV 5.0 83.0 6.0 5.5 0.5 - - - 81.5 18.0 0.5 - - - - -
a3PT.Pnimarytumour: P. pleuraleffusion; A. ascites; Gi1,G2. G3. tumourgradeaccording to Bloom -Scarff Richardson. 'Mean ofcounting results
by two investigators. 'Tumour staging according to UICC.
and cancerous specimens, which is to be expected using
centromeric probes (Kibbelaar et al.. 1993).
Results
This study was performed to determine copy numbers of
chromosomes 11 and 17 in breast cancer cells. In leucocyte
nuclei from four different normal controls, two signals for
chromosomes and 17 were observed in a mean (± stan-
dard deviation, s.d.) of 88.2% ± 0.95% and 87.3% ± 1.21%
respectively. Remaining cells appeared either monosomic
(Il1.3% ±0.58% and 12.0%±l1.27% respectively) or tri-
somic 0.5%± 0.46% and 0.7% ± 0.3% respectively), in good
agreement with results obtained by other investigators (East-
mond and Pinkel, 1990; Kibbelaar et al., 1993). Cells with
more than three signals were not detectable in any control
and therefore considered as unambiguously aneuploid in
cancerous specimens. To distinguish monosomy and trisomy
from background, cut-off levels were set at 3 s.d. above the
mean percentages of control cells with one and three signals
respectively, following the stringent criteria applied pre-
viously (e.g. Bentz et al., 1993). Since non-malignant cells
were present to a certain extent, the frequencies of aneuploid
tumour cells listed in Table I may be an underestimation in
some specimens.
Evaluation of specimens from 30 breast cancer patients
Pathological grading. stage of the disease and FISH findings
of 17 primary tumour and 13 effusion specimens are listed in
Table Chromosomal abnormalities were identified by FISH
in all cases (Figure la-c). For chromosome 11, aneuploidy
rate (defined as the percentages of one- and three-spot cells
above cut-off levels plus that of cells exhibiting more than
three signals) ranged from 1% (patient 16) to 83.5% (patient
1) (median 27.30o), and for chromosome 17 from 1.5%
(patient 10) to 92.O0o (patient 22) (median 49.9%). Combin-
ing FISH results for both chromosomes. median aneuploidy
rate was 5900 in the specimen with the lowest number
of chromosomally aberrant cells 6% (patient 9). A gain
of centromeric signals representing chromosome 11 was
observed in 1000 and representing chromosome 17 in only
870o, of the cases; in 13%. the majority of cells had loss of
chromosome 17 signals, most likely corresponding to
monosomy 17 (p~atients 3. 8. 29 and 30). There were always
heterogenous cell populations, mostly with a wide range of
chromosome 11I and 17 signal numbers (Table I). In ten cases
(33%). rare 'giant nuclei' with up to 14 and 18 centromeric
signals for chromosomes 11I and 17 respectively, were present
(exemplified in Figure ic). No relationship between breast
carcinoma grade stage and the pattern of aneuploidy by
FISH (Table I) was observed.
Evraluation of malignant cells from axillarv- lI-mph nodes
The finding of heterogenous subpopulations in primary
tumours prompted us to address the question if particular
subpopulations have a preferential tendency to dissemination.
Thus. we determined aneuploidy rates for chromosomes 11I
and 17 in tumour-inifiltrated axillary lymph nodes from five
patients. which were compared with that in the correspond-
ing primary tumours. In nodes from two patients (cases 7
and 17). chromosomal status was slightly more complex,
whereas in nodes from the other three patients diversity of
chromosomal aberrations appeared to be lowered (Figure 2).
Taken together, these data point to chromosomal hetero-
geneity in metastases closely related to that in primary
tumours.
FISH as diagnostic tool in cy-tologically- unclear effusions
By cytological criteria, cells from effusions obtained from
three patients (cases 21. 28 and 30) could not bve conclusively
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Figwe 1 Detection of chromosomal aberrations in breast cancer cells by centromere-specific FISH probes for chromosomes 11 or
17. (a) Primary tumour specimen from patient 1 with nuclei showing two, three and six signals representing chromosome 11. (b)
Primary tumour cells from patient 6 demonstrating predominance oftrisomy 17. (c) Primary tumour specimen from patient 13 with
nuclei showing four and five signals for chromosome 17 and a 'giant nucleus' with 18 signals. (d and e) Ascites cells from patient 30
with one signal for chromosome 17 (d) and two and four signals for chromosome 11 (e).
interpreted as being malignant. Using FISH, cell populations
exhibiting chromosomal changes consistent with malignancy
were detected (Table I. Figure Id and e). Metaphase
cytogenetics performed on an aliquot of samples from
patients 28 and 30 revealed abnormal karyotypes with com-
plex chromosomal abnormalities, confirming the results
obtained by FISH (Table II).
Eiscussion
Interphase cytogenetics. by which many cells can be screened
independent of their capacity to proliferate in vitro, has
evolved as a complementary tool to metaphase karyotyping
to thoroughly characterise cells in cancer specimens. Further-
more, FISH may become a valuable technique to obtain
cytogenetic information possibly correlating with clinical and
pathological features. FISH may thus represent a diagnostic
tool that can be used on a routine basis (Escudier et al.,
1993; Bandyk et al., 1994; Takahashi et al., 1994). The
feasibility of performing interphase cytogenetics in breast
cancer cells was demonstrated by the identification of
numerical chromosomal aberrations (Devilee et al., 1988;
Kallioniemi et al., 1992; Micale et al., 1994), deletions (Mat-
sumura et al.. 1992) or oncogene amplifications (Kallioniemi
et al., 1992). Aberrations of chromosomes 11 and 17 have
been associated with tumonrgenesis and prognosis (Dutrillaux
et al., 1990; Takita et al., 1992; Zafrani et al.. 1992; Winqvist
et al., 1993; Kallioniemi et al., 1994; Kirchweger et al., 1994),
and therefore our interest was focused on these chromo-
somes.
Using centromeric probes, we detected cell populations
with abnormalities of chromosomes 11 and 17 in all speci-
mens from the 30 patients studied. Previous FISH studies
provided only indirect information on centromeric copy
numbers of chromosome 17 in breast cancer cells (Kal-
lioniemi et al., 1992; Matsumura et al., 1992). The data
presented here support the hypothesis raised by recent inves-
tigations that breast tumours with a diploid karyotype may
occur at a much lower frequency than previously assumed
(Beerman et al.. 1991; Gnant et al., 1993; Kotliar et al.,
1993).
It should be taken into account that FISH with probes for
centromeric sequences may point to not only numerical, but
also structural chromosomal aberrations, particularly re-
arrangements, which have been reported to occur frequently
in juxtacentromeric regions in breast cancer cells (Dutrillaux
et al., 1990). Thus. translocation or loss of a part of the
centromeric region might be the reason for hybridisation
signals appearing relatively small, as indeed observed in
several specimens (Figure Ic).
Genetic evolution of breast cancer cells is often reflected byInterphase cytogenetics in breast cancer
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Patient 7 Patient 17 Patient 13 Patient 15 Patient 11
Figure 2 Comparison of centromere copy numbers (top, chromosome 11; bottom, chromosome 17) between primary tumour (PT)
and axillary lymph node (LN) metastases from five breast cancer patients. Frequency of cells with one (LI]), two ( E ), three
( R ) and _ 4 ( ) copies are symbolised by bars as indicated. In nodal metastases of patients 7 and 17, an increased diversity
of chromosomal aberrations was observed compared with the corresponding primary tumours, whereas in patients 13, 15 and 11
there was a tendency to less complexity. The higher fraction of nodal cells with two signals for the chromosomes examined may be
due to the significant presence of lymphocytes which were not excluded from evaluation (see Materials and methods).
Table II Karyotypes of ascites cells from patients 28 and 30
Patient 28
69.XXX. +t(l;9) (q31;p21). +t(1;14) (qlO;qlO) +del (1) (q21q41),
-2. -3. -4. -5. -6. +7. -9, -9. -9, -ll,del(l1)(q14) x 2,-12,
t(9:13) (qlO;ql2). t(13;15) (plO;qlO). - 17. - 18. - 18, [cp 8]
Patient 30
46.XX. t(l1:9) (q2lplO). t1;21) (q21:q12). -2. t(4.21) (pl :ql2). -6.
-7. -7. -8. +10. -11. del (11) (q14q22). add (12) (q24). t(13;14)
(plO;qlO). t(I4.15) (plO;qlO)q -14. -14. t(l6;17) (qI 1:q12), -17. del
(18) (q21). +20, [cp6]
accumulation of rearrangements (mostly being associated
with loss of DNA) and by subsequent endoreduplication.
resulting in hyperploid clones and, thus, leading to genetic
diversity (Dutrillaux et al.. 1991; Devilee and Cornelisse.
1994). Our finding of varying signal number distributions for
both chromosomes was indicative of inter- and intra-tumour
heterogeneity. mostly to a marked extent (Table I). This is
highlighted by the finding of rare 'giant nuclei' with high
copy numbers of centromeres (Figure Ic). In a previous
study. the presence of rare breast cancer cells with highly
elevated DNA contents probably resulting from multiple
endoreduplication events was observed by DNA image
cytometry (Cornelisse and Van Driel-Kulker. 1985).
No correlation was found between patient age, histological
tumour grade. tumour stage and aneuploidy pattern by
FISH. Likewise. we could not define subpopulations which
might preferentially disseminate to positive axillary lymph
nodes with the FISH probes used here. Rather, it may be
assumed that tumour heterogeneity evolves in a similar way
in both primary tumour and metastatic lesions. Together.
these findings suggest that acquirement of genetic instability
leading to clonal diversity is an early event, in agreement
with previous reports (Heim et al., 1988; Dutrillaux et al.,
1991; Shay et al., 1993). To determine if particular features
defined by FISH in early-stage primary tumours will indicate
risk of relapse, more patients will be investigated prospec-
tively.
Cells from one pleural effusion and two ascites were
difficult to interpret as reactive or malignant by cytology, but
populations with aneuploidies were identified by FISH. Thus,
the addition of FISH allowed for the unequivocal iden-
tification of those specimens as being malignant. Metaphase
preparations from the two ascites specimens revealed com-
plex karyotypes confirming the FISH results. The finding
that all primary and metastatic breast cancer specimens
appear to exhibit chromosomal changes by FISH implies that
tumour cell identification might be improved by the addition
of FISH. In unclear effusions, this would be a major con-
tribution because other techniques such as DNA ploidy
measurement or immunocytochemistry were shown to lack
absolute sensitivity and or specificity (Diaz-Arias et al., 1993;
Baars et al., 1994; Banks et al., 1994; Rodriguez de Castro et
al.. 1994). In a similar approach, FISH of bladder wash
specimens was successfully performed to detect malignant
cells of transitional cell cancer (Cajulis et al., 1994).
However, it remains to be established whether FISH
screening is superior to immunostaining for the detection of
breast tumour cells in bone marrow or stem cell harvests
(Brugger et al.. 1994: Menard et al.. 1994).
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